REG - Oxford Biomedica PLC - Axovant update on AXO-Lenti-PD and virtual R&D day

Oxford BioMedicaAnnouncement

30/10/2020 07:01

RNS Number : 6943D
  
Oxford Biomedica PLC
  
30 October 2020
  
 

 
 
Oxford Biomedica notes Axovant's update on AXO-Lenti-PD and presentation of programme at virtual R&D day on October 30, 2020
 
          
Oxford, UK - 30 October, 2020: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, notes Axovant Gene Therapies' ("Axovant") update on AXO-Lenti-PD gene therapy programme in Parkinson's disease.
 
Key points to note from the release are as follows:
 
·      Patient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose response
·      Based on delays in CMC data and third-party fill/finish issues, the development of a suspension-based manufacturing process will take longer than expected. As a result, Axovant does not currently expect that a randomized, sham-controlled trial will enrol patients by the end of 2021
·      Program updates to be presented as part of Axovant's virtual R&D Day on Friday, October 30, 2020 at 11:30 AM EST
 
To view the full announcement from Axovant, please follow this link: LINK
 
 
In June 2018, Oxford Biomedica out-licenced OXB-102 (later renamed AXO-Lenti-PD) to Axovant through a $842.5 million worldwide licence agreement (LINK). In July 2020 a three year clinical supply agreement was additionally signed with Axovant to manufacture GMP batches to support the ongoing and future clinical development of AXO-Lenti-PD (LINK).
 
 
 
-Ends-




 
 
 
 
 
Enquiries:


 




 
Oxford Biomedica plc
 
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
 


 
 
 
T: +44 (0)1865 783 000
T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
 




 
Consilium Strategic Communications
 
Mary-Jane Elliott/Matthew Neal


 
 
 
T: +44 (0)20 3709 5700




 
 
 
 
 
 
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com
 
 
About Axovant Gene Therapies
Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson's disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com
 
 
About AXO-Lenti-PD
AXO-Lenti-PD is an investigational gene therapy for the treatment of Parkinson's disease that is designed to deliver three genes (tyrosine hydroxylase, cyclohydrolase 1, and aromatic L-amino acid decarboxylase) via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The investigational gene therapy aims to provide patient benefit for years following a single administration..
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCMLBTTMTJTTFM